6 months of Sirturo (Bedaquiline) tablets for the NIH (Notice of Intent to sole source)
ID: NOI-CC-25-000022Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH - CCBETHESDA, MD, 20892, USA

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/6082db041c2344fe9f3e55372b2752f2/view
Timeline
    Description

    The National Institutes of Health (NIH) intends to procure six months' supply of Sirturo (Bedaquiline) tablets through a sole-source contract with Cardinal Health, as part of its pharmaceutical care services for patients in clinical trials. The requirement includes approximately 12 to 36 bottles of 100 mg tablets in 188-count bottles and 20 mg tablets in 60-count bottles, with the expectation of needing up to 10 bottles of the former and up to 3 bottles of the latter per year. Sirturo is critical for patient care, as it is the only medication available for specific treatment needs, and Cardinal Health is the sole distributor authorized by the manufacturer, Janssen Therapeutics. Interested parties may submit capability statements by April 21, 2025, to Lu Chang at lu-chang.lu@nih.gov, as this is not a request for proposals.

    Point(s) of Contact
    Lu Chang
    lu-chang.lu@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    6505--Notice of Intent to Award a Sole Source Procurement - Xofigo Radium-223 dichloride
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, specifically the Network Contracting Office 17, intends to award a sole source, firm-fixed-price contract to Cardinal Health for the procurement of 660 units of XOFIGO® (Radium-223 dichloride). This procurement is based on a letter from Bayer Healthcare, which designates Cardinal Health as the sole distributor of XOFIGO® in the United States, highlighting the critical nature of this pharmaceutical in treating specific medical conditions. Interested parties may submit capability statements or proposals within seven days of the notice's publication, with the deadline set for December 19, 2025; otherwise, the contract will be awarded to Cardinal Health without further notice. For inquiries, contact Vance Farrell at vance.farrell@va.gov or call 210-694-6379.
    Rabeprazole Sodium Delayed Release Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    TheraDoc Hospital Epidemiology System subscription/renewal from Premier Healthcare LLC (Notice of Intent to Sole Source)
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to renew its subscription and support for the TheraDoc Hospital Epidemiology System from Premier Healthcare LLC. This procurement aims to ensure continued access to the TheraDoc clinical surveillance and infection control decision support system, which is vital for patient safety, infection prevention, and regulatory compliance at the NIH Clinical Center. The system aggregates and analyzes data from various clinical sources, providing real-time alerts and reports essential for daily operations. Interested parties may submit capability statements by December 15, 2025, to Lu Chang at lu-chang.lu@nih.gov, as this is a sole-source requirement with a performance period starting October 1, 2025, through September 30, 2026, with two additional option years.
    6505--Ustekinumab Pens/Syringes or Biosimilar
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Ustekinumab Pens/Syringes or Biosimilars, aimed at supplying various federal health entities including the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will be awarded for an initial period of one year, with the possibility of four additional one-year option periods, ensuring a consistent supply of these critical pharmaceutical products through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique National Drug Code (NDC) numbers and ensure that any biosimilar products meet FDA licensing requirements, as outlined in the FDA Purple Book. The solicitation is expected to be released around January 12, 2026, with a tentative closing date of January 27, 2026; interested parties should direct inquiries to Chris Carthron at Christopher.Carthron@va.gov or (708) 786-4980.
    Notice of Intent to Sole Source – Life Technologies Corp.
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to Life Technologies Corporation for the procurement of reagents and consumables necessary for operating Life Technologies instruments at the NIH Clinical Center's Department of Laboratory Medicine. This acquisition is critical as the reagents have been validated for specific assays, including BCR-ABL fusion, cKIT mutation, and JAK2 mutation assays, ensuring consistency in patient testing and avoiding potential delays in patient care that could arise from switching vendors. Interested parties may express their interest and capabilities to the NIH by contacting Kristin Nagashima at kristin.nagashima@nih.gov, with comments due by December 17, 2025, at 12 PM EST.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense (DoD) is issuing a Request for Quotation (RFQ) for pharmaceutical agents to be included in the Uniform Formulary (UF) as part of a Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) for Military Treatment Facilities (MTFs) and TRICARE pharmacies. This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of drugs, which will be evaluated by the Pharmacy and Therapeutics (P&T) Committee. Key drugs under consideration include newly approved agents for lung cancer, antihypertensive agents, oncological agents, diuretics, antilipidemics, and targeted immunomodulatory biologics, with quotes due by January 5, 2026, for a committee meeting scheduled for February 4-5, 2026. Interested manufacturers should contact Tracy Banks or Julia Trang via email for further details and ensure compliance with submission requirements outlined in the RFQ document HT9402-26-Q-9103.
    Trazodone - Solicitation
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting offers for Trazodone HCL tablets in various dosages and bottle counts. This procurement aims to fulfill substantial pharmaceutical supply needs, emphasizing compliance with technical and quality requirements as outlined in the solicitation documents. The solicitation, identified as SPE2D2-26-R-0003, mandates electronic submissions via the Defense Logistics Agency Internet Bid Board System (DIBBS) by December 12, 2025, at 3:00 PM EST, with no alternative submission methods accepted. Interested parties can reach out to Nancy Fernandez at nancy.fernandez@dla.mil or Jason Wray at jason.wray@dla.mil for further inquiries.
    6505--Zonisamide Capsules
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified suppliers for a Firm Fixed Price, Indefinite-Delivery Requirements contract for Zonisamide Capsules in 25mg, 50mg, and 100mg dosages. Offerors are required to provide pricing for a base year and four option years, submit a 0.5% Cost Recovery Fee, and comply with stringent packaging and barcoding standards, including adherence to the Drug Supply Chain Security Act (DSCSA) and National Drug Code (NDC) requirements. These pharmaceutical products are crucial for the healthcare services provided to veterans and military personnel through the VA and DoD Pharmaceutical Prime Vendor Programs. Interested parties should contact Contract Specialist Christopher Carthron at Christopher.Carthron@va.gov for further details, and ensure they meet all compliance and registration requirements, including current SAM registration.
    COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM - 762 TUCSON
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is conducting a Sources Sought Notice to identify potential qualified domestic sources for the procurement of COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM through its National CMOP Office. This announcement serves as a market research tool rather than a solicitation, aiming to gather information on vendors' capabilities to meet the requirements outlined in the Statement of Requirements. The products sought are critical for pharmaceutical preparation and will support the healthcare needs of veterans. Interested vendors must submit their responses, including company details and capability statements, via email to Jennifer Coleman at Jennifer.Coleman4@va.gov by December 19, 2025, at 3:00 PM CDT. This notice does not obligate the VA to issue a solicitation.
    Notice of Intent to Award / Sole Source - Pyxis Automated Dispensing Systems for controlled drugs & medication services - Tsaile Health Center
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Indian Health Service's Navajo Area Indian Health Service, intends to award a sole source contract to CareFusion Solutions LLC for the provision of Pyxis Automated Dispensing Systems, which are critical for managing controlled drugs and medication services at the Tsaile Health Center in Arizona. This procurement is essential to ensure uninterrupted patient care, as the existing systems are already installed and operational, and CareFusion holds proprietary rights to the necessary technology. The anticipated period of performance for this contract is from January 1, 2026, to December 11, 2026, with four additional one-year option periods. Interested parties may contact Bennett Arvessto at bennett.arvessto@ihs.gov for further information, although responses to this notice will not be considered competitive proposals.